PPT-Personalized Therapy in Relapsed or Refractory CLL

IWCLL Criteria for Treating CLL Other Considerations at Relapse Risk Factors at Relapse IGHV Status Affects Clinical Course Case 1 65YearOld Man Assessing This Patients Options TP53 Mutationdel17p and CIT. Impact . on t. iming . of . therapy. Nicholas Chiorazzi. The Feinstein Institute for Medical Research. North Shore – LIJ Health System. Manhasset, NY. At all points in time, CLL clones are heterogeneous based on a number of criteria. New agents timing?. Agne Paner, MD. Assistant professor of Medicine. RUSH University Medical Center. Blood Smear in CLL. Chronic Lymphocytic Leukemia. Most prevalent type of adult leukemia . 30% of all . CLL/SLL. Use of Markers in Nonclinical Trial Practice. CLL/SLL. Frontline Therapy. CLL/SLL. Second-line Therapy. CLL/SLL. Cure vs Indefinite Therapy. CLL/SLL. CART-19 Therapy. Topics. Current Treatment Options for Relapsed/Refractory Multiple Myeloma. Topics. Relapsed/Refractory MM. Treatment Goals and Strategies. Relapsed/Refractory MM. Exposure to Stem Cell Toxic Agents Not An Issue for Most Patients . Ruben Niesvizky. Myeloma Center. Myelomacenter.org. run9001@med.cornell.edu. Multiple Myeloma: Natural History of Disease. Durie B; International Myeloma Foundation. . Concise review of the disease and treatment options: multiple myeloma. 2011/2012 edition;. therapy in relapsed/refractory myeloma: . A UK multi-centre experience. Neil Rabin. Consultant Haematologist. o. n behalf of Dr Nicola . Maciocia. University College London Hospitals, UK. 4. th. November 2015. ASH Review 2012. Stephen Spurgeon (spurgeos@ohsu.edu). Disclosures. Speakers Bureau: GSK, . Millenium. , . Cephalon. CLL: Pertinent Topics. ASH treatment updates. James DF, et al. ASH 2011. Abstract 291.. USE OF ANAESTHETIC AGENTS. R MAHARAJ. LECTURE OUTLINE. CURRENT CONCEPTS ON DEFINITION AND MANAGEMENT. DEFINITIONS. ANEASTHETIC AGENTS USED. THE IDEAL ANAESTHETIC AGENT. SUMMARY. CURRENT THINKING??. More aggressive and early treatment of seizures. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. Utku Uysal, M.D. M.S.. Seizure: . “a . transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain. The term transient is used as demarcated in time, with a clear start and finish.” . Case Discussion A 64-year old woman diagnosed with monoclonal gammopathy of undetermined significance (MGUS ) in September 2015 She has been monitored over time and has had a slight increase in her proteins. Bertrand Coiffier. Service d. ’. Hématologie. Hospices Civils de Lyon. Equipe . « Pathologie des Cellules Lymphoïdes ». UMR 5239 CNRS – UCB – ENS - HCL. The Lymphoma. Study Association. One question, lot of possibilities. Pan - London Haemato - O ncology Clinical G Lymphoid M alignancies Part 4: Chronic Lymphocytic Leuk a emia (CLL) and B - prolymphocytic L eukaemia (B - PLL ) January 2020 CONTENTS 2 Contents 1 Introd Mallaig. Sprinkling Song . Spirit of God, come dwell within me..  . Open my heart, O come set me free. . Fill me with love for Jesus, my Lord.. O fill me with living water.. Jesus is living, Jesus is here. .